INOGEN INC (INGN) Stock Fundamental Analysis
USA - NASDAQ:INGN - US45780L1044 - Common Stock
8.41 USD
-0.12 (-1.41%)
8.41 USD
0 (0%)
INGN gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 189 industry peers in the Health Care Equipment & Supplies industry. No worries on liquidiy or solvency for INGN as it has an excellent financial health rating, but there are worries on the profitability. INGN is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
INGN had negative earnings in the past year.
INGN had a negative operating cash flow in the past year.
In the past 5 years INGN always reported negative net income.
In multiple years INGN reported negative operating cash flow during the last 5 years.
1.2 Ratios
INGN has a better Return On Assets (-8.35%) than 64.02% of its industry peers.
INGN has a Return On Equity of -13.06%. This is in the better half of the industry: INGN outperforms 64.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.35% | ||
| ROE | -13.06% | ||
| ROIC | N/A |
ROA(3y)-21.41%
ROA(5y)-13.35%
ROE(3y)-32.95%
ROE(5y)-20.44%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
INGN's Gross Margin of 45.23% is on the low side compared to the rest of the industry. INGN is outperformed by 60.85% of its industry peers.
In the last couple of years the Gross Margin of INGN has remained more or less at the same level.
INGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 45.23% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.22%
GM growth 5Y-0.6%
2. Health
2.1 Basic Checks
INGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, INGN has more shares outstanding
The number of shares outstanding for INGN has been increased compared to 5 years ago.
There is no outstanding debt for INGN. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
INGN has an Altman-Z score of 1.78. This is a bad value and indicates that INGN is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of INGN (1.78) is comparable to the rest of the industry.
INGN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 1.78 |
ROIC/WACCN/A
WACC8.63%
2.3 Liquidity
INGN has a Current Ratio of 3.03. This indicates that INGN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 3.03, INGN is in the better half of the industry, outperforming 60.32% of the companies in the same industry.
A Quick Ratio of 2.67 indicates that INGN has no problem at all paying its short term obligations.
INGN has a Quick ratio of 2.67. This is in the better half of the industry: INGN outperforms 64.02% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.03 | ||
| Quick Ratio | 2.67 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 58.43% over the past year.
Looking at the last year, INGN shows a small growth in Revenue. The Revenue has grown by 5.14% in the last year.
Measured over the past years, INGN shows a decrease in Revenue. The Revenue has been decreasing by -1.49% on average per year.
EPS 1Y (TTM)58.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
Revenue 1Y (TTM)5.14%
Revenue growth 3Y-2.12%
Revenue growth 5Y-1.49%
Sales Q2Q%3.96%
3.2 Future
The Earnings Per Share is expected to grow by 23.99% on average over the next years. This is a very strong growth
INGN is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.65% yearly.
EPS Next Y35.24%
EPS Next 2Y21.51%
EPS Next 3Y23.99%
EPS Next 5YN/A
Revenue Next Year7.96%
Revenue Next 2Y8.49%
Revenue Next 3Y6.65%
Revenue Next 5YN/A
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
INGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INGN. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
INGN's earnings are expected to grow with 23.99% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y21.51%
EPS Next 3Y23.99%
5. Dividend
5.1 Amount
INGN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
8.41
-0.12 (-1.41%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners74.25%
Inst Owner Change-0.05%
Ins Owners2.07%
Ins Owner Change6.35%
Market Cap227.41M
Revenue(TTM)343.47M
Net Income(TTM)-26046000
Analysts77.78
Price Target13.26 (57.67%)
Short Float %3.08%
Short Ratio4.02
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)47.79%
Min EPS beat(2)44.85%
Max EPS beat(2)50.73%
EPS beat(4)4
Avg EPS beat(4)45.01%
Min EPS beat(4)33.97%
Max EPS beat(4)50.73%
EPS beat(8)6
Avg EPS beat(8)21.05%
EPS beat(12)9
Avg EPS beat(12)21.34%
EPS beat(16)11
Avg EPS beat(16)35.06%
Revenue beat(2)1
Avg Revenue beat(2)0.63%
Min Revenue beat(2)-0.15%
Max Revenue beat(2)1.4%
Revenue beat(4)3
Avg Revenue beat(4)2.75%
Min Revenue beat(4)-0.15%
Max Revenue beat(4)6.23%
Revenue beat(8)5
Avg Revenue beat(8)2.1%
Revenue beat(12)6
Avg Revenue beat(12)0.22%
Revenue beat(16)9
Avg Revenue beat(16)0.64%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)5.71%
EPS NQ rev (3m)-3.13%
EPS NY rev (1m)0%
EPS NY rev (3m)6.91%
Revenue NQ rev (1m)0.07%
Revenue NQ rev (3m)-1.14%
Revenue NY rev (1m)0.17%
Revenue NY rev (3m)0.61%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.66 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.14 | ||
| P/tB | 1.46 | ||
| EV/EBITDA | N/A |
EPS(TTM)-1.06
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-0.83
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS12.7
BVpS7.38
TBVpS5.75
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -8.35% | ||
| ROE | -13.06% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 45.23% | ||
| FCFM | N/A |
ROA(3y)-21.41%
ROA(5y)-13.35%
ROE(3y)-32.95%
ROE(5y)-20.44%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.22%
GM growth 5Y-0.6%
F-Score6
Asset Turnover1.1
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 66.83% | ||
| Cap/Sales | 4.05% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 3.03 | ||
| Quick Ratio | 2.67 | ||
| Altman-Z | 1.78 |
F-Score6
WACC8.63%
ROIC/WACCN/A
Cap/Depr(3y)106.82%
Cap/Depr(5y)105.29%
Cap/Sales(3y)6.42%
Cap/Sales(5y)6.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%37.5%
EPS Next Y35.24%
EPS Next 2Y21.51%
EPS Next 3Y23.99%
EPS Next 5YN/A
Revenue 1Y (TTM)5.14%
Revenue growth 3Y-2.12%
Revenue growth 5Y-1.49%
Sales Q2Q%3.96%
Revenue Next Year7.96%
Revenue Next 2Y8.49%
Revenue Next 3Y6.65%
Revenue Next 5YN/A
EBIT growth 1Y51.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year103.09%
EBIT Next 3Y31.24%
EBIT Next 5YN/A
FCF growth 1Y59%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y68.91%
OCF growth 3Y-36.98%
OCF growth 5Y-31.97%
INOGEN INC / INGN FAQ
What is the fundamental rating for INGN stock?
ChartMill assigns a fundamental rating of 3 / 10 to INGN.
What is the valuation status of INOGEN INC (INGN) stock?
ChartMill assigns a valuation rating of 1 / 10 to INOGEN INC (INGN). This can be considered as Overvalued.
How profitable is INOGEN INC (INGN) stock?
INOGEN INC (INGN) has a profitability rating of 2 / 10.
Can you provide the financial health for INGN stock?
The financial health rating of INOGEN INC (INGN) is 7 / 10.